CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-07260437 | New project
Breast Cancer Metastatic (Biologic)
B7H4-CD3 bispecific
PF-07062119 | New project
Advanced/Metastatic Gastrointestinal Cancer (Biologic)
GUCY2c CD3 bispecific antibody
PF-08046045 (SGN-35T) | Project advanced
Advanced Solid Tumors and Lymphomas (Biologic)
CD-30 directed antibody-tripeptide MMAE conjugate
PF-08046050 (SGN-CEACAM5C) | Project advanced
Advanced Solid Tumors (Biologic)
CEACAM5-directed antibody-drug conjugate
PF-08046040 (SGN-CD70) | Project advanced
Myelodysplastic Syndrome and Acute Myeloid Leukemia (Biologic)
Non-fucosylated CD70-directed antibody
PF-08046054 (SGN-PDL1V) | Project advanced
Advanced Solid Tumors (Biologic)
PD-L1-directed antibody-drug conjugate
PF-08046052 (SGN-EGFRd2) | Project advanced
Advanced Solid Tumors (Biologic)
EGFR-targeted bispecific gamma delta T-cell engager
SGN-B7H4V | Project advanced
Advanced Solid Tumors (Biologic)
B7H4-directed antibody-drug conjugate
SGN-B6A | Project advanced
Advanced Solid Tumors (Biologic)
Integrin beta-6-directed antibody-drug conjugate
PF-08046049 (SGN-BB228) | Project advanced
Advanced Melanoma and Other Solid Tumors (Biologic)
CD228-directed antibody-Anticalin bispecific protein3
TIVDAK (tisotumab vedotin) | Project advanced
Recurrent or Metastatic Cervical Cancer (Biologic)
Tissue Factor-directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | Project advanced
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
TUKYSA (tucatinib) | Project advanced
HER2+ Gastrointestinal Cancers (SGNTUC-024)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | Project advanced
Urothelial Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-07248144 + PF-07220060 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier + CDK4 inh
PF-07799544 | New project
Solid Tumors
MEK brain penetrant inhibitor
PF-07220060 + enzalutamide | New project
Prostate Cancer
CDK4 inhibitor
PF-07104091 | New project
Ovarian Cancer
CDK2 inhibitor
PF-07799933 | New project
Solid Tumors
BRAF Class 1 and Class 2 inhibitor
PF-07104091 + PF-07220060 | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
PF-07284892 | New project
Solid Tumors
SHP2 tyrosine phosphatase inhibitor
PF-07248144 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier
PF-07104091 | New project
Breast Cancer Metastatic
CDK2 inhibitor
PF-06940434 | New project
Solid Tumors (Biologic)
Integrin alpha-V/beta-8 antagonist
Disitamab vedotin (DV) | Project advanced
Locally Advanced or Metastatic Solid Tumors with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
Disitamab vedotin (DV) | Project advanced
2L+ Urothelial Cancer with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | Project advanced
Locally Advanced or Metastatic Solid Tumors with HER2 Alterations
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | Project advanced
2L+ Metastatic Urothelial Cancer (HER2 Expression)
HER2 tyrosine kinase inhibitor
TIVDAK (tisotumab vedotin) | Project advanced
Advanced Solid Tumors (Biologic)
TF directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | Project advanced
Locally Advanced or Metastatic Solid Tumors (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-07220060 | New project
Breast Cancer Metastatic
CDK4 inhibitor
PF-06821497 + enzalutamide | New project
Prostate Cancer
EZH2 inhibitor
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa fusion protein
vepdegestrant (ARV-471) | New project
ER+/HER2- Early Breast Cancer
ER-targeting PROTAC protein degrader
Disitamab vedotin (DV) | Project advanced
1L HER2 (=IHC1+) Metastatic Urothelial Cancer (SGNDV-001) (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | Project advanced
1L HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | Project advanced
1L HER2+ Maintenance Metastatic Breast Cancer (HER2CLIMB-05)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | Project advanced
2L/3L HER2+ Metastatic Breast Cancer (HER2CLIMB-02)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | Project advanced
HER2+ Adjuvant Breast Cancer (CompassHER2 RD)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | Project advanced
Cisplatin-Eligible Muscle-Invasive Bladder Cancer (EV-304) (Biologic)
Nectin-4 directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | Project advanced
Cisplatin-Ineligible/Decline Muscle-Invasive Bladder Cancer (EV-303) (Biologic)
Nectin-4 directed antibody-drug conjugate
IBRANCE + vepdegestrant (ARV-471) | Project advanced
ER+/HER2- Metastatic Breast Cancer (VERITAC 1)
CDK 4,6 kinase inhibitor ER-targeting PROTAC protein degrader
vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer (VERITAC 2)
ER-targeting PROTAC protein degrader
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (MM-6) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (MM-7) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Multiple Myeloma Double-Class Exposed (MM-5) (Biologic)
BCMA-CD3 bispecific antibody
BRAFTOVI (encorafenib) + ERBITUX (cetuximab) + chemotherapy | New project
1st line BRAF-Mutant Metastatic Colorectal Cancer (BREAKWATER)
BRAF kinase inhibitor
TALZENNA (talazoparib) | New project
Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-Deficient Metastatic Castration Sensitive Prostate Cancer (TALAPRO-3)
PARP inhibitor
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
Non-Muscle-Invasive Bladder Cancer (CREST) (Biologic)
Anti-PD-1
IBRANCE (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA)
CDK 4,6 kinase inhibitor
TIVDAK (tisotumab vedotin) | Project advanced
Recurrent or Metastatic Cervical Cancer (innovaTV 301) (Biologic) (PRIORITY REVIEW - U.S.)
TF-directed antibody-drug conjugate